MAY 25, 2016 10:30 AM PDT

"Supercharging" Natural Killer Cells to Kill Cancer

WRITTEN BY: Kara Marker
Humans have specialized immune cells designed to detect and kill abnormal cells, whether they are virally-infected or cancerous cells. However, cancer cells can change to survive in their environment just like bacterial like Staphylococcus aureus evolve to have antibiotic resistance and scientists have to create a new influenza vaccine every year due to seasonal mutations. Likewise, cancer cells adapt to evade the immune cells, so researchers develop treatments to fight back, “supercharging” immune cells to avoid evasion.
 
For attacking cancerous cells, natural killer (NK) cells are the soldier of choice. NK cells identify and kill cancer cells as abnormal and then release chemicals that cause cell lysis. In a collaborative study between researchers from the Walter and Eliza Institute and Queensland Institute of Medical Research, scientists identified a way to reactivate NK cells that have been “silenced” by cancer cells.

NK cells require signals from an immune growth factor called interleukin (IL) 15. Interleukins are chemical messengers that communicate with dozens of immune cells, and IL-15 regulates the activation and proliferation of NK cells. However, NK cells contain an inhibitor that prevents them from adequately attacking cancer cells, rendering them unable to detect and kill cancerous cells before they divide and spread.
 
The current study, published in Nature Immunology, took an experimental model of metastatic melanoma to see if a drug that targeted the NK cell inhibitor would successfully reactivate NK cells to promote continuous, powerful cancer cell attacks. Metastatic melanoma is a late-stage cancer that described a state of cancer spread to the lymph nodes and “distant sites in the body and the body’s organs,” including the liver, lungs, bones, and brain.
 
In the experimental cancer model, removing the inhibitor did help NK cells target and kill cancer cells, and scientists are hopeful that a drug developed to do so could achieve the same result, and not just in cases of metastatic melanoma, but many other cancer types.
 

Sources: Walter and Eliza Hall Institute, Melanoma Research Foundation, National Center for Biotechnology Information, Centre d'Immunologie de Marseille-Luminy
 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
JUL 18, 2018
Immunology
JUL 18, 2018
Immunotherapy Increases Survival of Melanoma Brain Metastases Patients
Use of Checkpoint Blockade Immunotherapy increases survival rates in Melanoma Brain Metastases patients, with a 4-year survival rate increase from 11.1% to 28.1%...
AUG 04, 2018
Immunology
AUG 04, 2018
Infant's Innate Immune Response
An infant's innate immune response develops from fetus to birth, but it may not be as "immature" as previously thought....
SEP 07, 2018
Health & Medicine
SEP 07, 2018
What's Behind the Massive Measles Outbreak in Europe?
Measles is a disease that many believe was eradicated years ago. That's true, to a point, but like a bad penny, it's back. In the United States, th...
SEP 11, 2018
Cannabis Sciences
SEP 11, 2018
The Potential Anti-cancer Effects of Cannabinoids
They're known for helping to reduce the impact of cancer drug side effects, but it's possible that cannabinoids themselves are cancer fighters....
SEP 26, 2018
Neuroscience
SEP 26, 2018
Therapeutic antibodies for Alzheimer's disease: challenges and hopes
Solanezumab: this simple name evokes at the same time one of the greatest hopes and the worst disillusions for Alzheimer’s Disease (AD) patients. Two...
NOV 14, 2018
Immunology
NOV 14, 2018
Rapid Tumor Targeting
Researchers at the University of California Irvine have developed a technology that will rapidly identify and target T cell receptors for tumor specific antigens...
Loading Comments...